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• Perioperative bleeding during prostate surgery is still a common morbidity.
• Anticoagulant and antiplatelet medications contribute to the risk of hemorrhage and prolonged hospital stay.
• Multiple pharmacological agents have been proposed, but none of them have been widely accepted.
• It is crucial to find a safe and effective modality to reduce hemorrhage.
Summary. Background: Hemorrhage during transurethral resection of the prostate (TUR-P) has always been a concern. Several studies have shown preoperative administration of fibrinogen concentrate to have promising results in reducing hemorrhage in cardiac surgery. Objectives: To investigate the hemostatic effect of fibrinogen concentrate administration on reducing the amount of bleeding during TUR-P in patients with benign prostatic hyperplasia. Methods: Sixty men with benign prostatic hyperplasia, who were chosen to undergo TUR-P, entered this prospective randomized double-blind placebo-controlled study. The participants were randomly assigned to two groups: treatment (n = 31) and placebo (n = 29). They received an infusion of 2 g of fibrinogen concentrate (treatment group) or normal saline (placebo group) before surgery. Data regarding the amount of bleeding, the operation and complications were recorded and analyzed. Results: No difference was observed in bleeding between the fibrinogen and placebo groups during (521 mL versus 557 mL, respectively) and after (291 mL versus 341 mL, respectively) surgery. This lack of difference was also seen in operation time (43 min versus 42 min), irrigating fluid volume used during (17 L versus 19 L) and after (29 L versus 28 L) surgery, and resected adenoma volume (19 g versus 19 g ). The mean blood pressure was also similar in
Introduction
Prostatectomy by transurethral resection of the prostate (TUR-P) has been used for decades, and is still considered to be the standard surgery [1] . A major complication during and immediately after TUR-P surgery is bleeding, which results in morbidity [2] . The contributory factors are operation time (> 90 min), prostate volume (> 45 g), resected tissue weight, anesthesia type, malignant histology, blood pressure, large-scale irrigation fluid absorption, preoperative finasteride treatment, age, and aspirin use history [1] [2] [3] [4] [5] . Some medications and methods have been recommended to reduce the amount of bleeding, such as improving surgical technique and skill [6] , and using innovative resection devices such as bipolar or laserequipped resectoscopes [6, 7] . Furthermore, non-surgical approaches, including intravesical aminocaproic acid, intravenous estrogen administration, intraprostatic vasopressin, fibrin adhesive, phenol solution, and preoperative finasteride or tranexamic acid administration, have also been tried [5, 6, [8] [9] [10] . Although finasteride and tranexamic acid yield favorable results [4, 5] , they need to be prescribed before surgery. They are ineffective in the emerging bleeding conditions during and after surgery.
Despite these approaches with promising results, there is still no effective method or medication to significantly reduce the amount of blood loss during and after prostate surgeries for benign prostatic hyperplasia, including TUR-P. Considering the widespread use of TUR-P, finding a safe and effective medication for inadvertent hemorrhage control is a necessity, and can reduce costs, non-working days, morbidity, and even mortality.
Recently, in major trauma patients or those with elective surgeries with risks of excessive bleeding (e.g. cardiac surgery), administering fibrinogen supplementation has demonstrated acceptable results [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Its administration is recommended to maintain plasma fibrinogen levels of > 1.5 g L À1 [21] . In 2013, the European guideline for bleeding and coagulopathy management following major trauma recommended the use of fibrinogen when the plasma level is < 2 g L À1 or if thromboelastometric signs of functional fibrinogen deficit exist [21] . As a key element in the coagulation cascade [22, 23] , fibrinogen is synthesized in the liver, and, as it is only available in plasma, it is the first coagulating factor to fall to a suboptimal level early during bleeding and dilutional coagulopathy [24] . There are three available fibrinogen sources for clinical use: fibrinogen concentrate, fresh frozen plasma, and cryoprecipitate. Fibrinogen concentrate is derived from human plasma that is highly purified, pasteurized, and lyophilized. It is the only form of fibrinogen that can be used outside the hospital, and does not need blood type compatibility. It can be stored at 25°C for 5 years, and is easily prepared and administered. It is virally inactivated by heat treatment. A high level of fibrinogen (20 g L À1 ) can be replaced with a small volume (200 mL for 4 g of fibrinogen). This is in contrast to cryoprecipitate, which has a variable level of fibrinogen (8-16 g L
À1
), and to fresh frozen plasma, which has a much lower level of fibrinogen (2 g L À1 ). They need to be administered in larger volumes, which might lead to volume overload [25] [26] [27] .
Despite previous experiences in blood loss control with fibrinogen concentrate in various surgical fields [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , questions about its effectiveness in prostatectomy patients still remain. Hence, this clinical trial investigated the effects and possible adverse effects of fibrinogen concentrate on the amount of bleeding in men undergoing TUR-P. To the authors' knowledge, this is the first study on administering fibrinogen supplementation as a hemostatic strategy in men undergoing TUR-P.
Materials and methods
From August 2014 to September 2015, 60 men who were chosen to undergo TUR-P surgery in our hospital were recruited for this study. The hospital is an educational, high-volume tertiary urology center. All participants were screened for the inclusion criteria which was clinical and laboratory evidence of benign prostatic hyperplasia (Fig. 1) .
The exclusion criteria were as follows: having a previous history of prostate cancer or prostatectomy; taking finasteride or any anticoagulant agent; having a known blood abnormality or coagulopathy; a history of thromboembolism; chronic liver disease; chronic kidney disease with a serum creatinine level of > 2 mg dL À1 ; and a preoperative plasma fibrinogen level of ≥ 400 mg dL
À1
. The rationale for selecting this limit was to ascertain that no patient in the treatment group had a fibrinogen level exceeding the limit of 400 mg dL À1 following the infusion. In addition, if the histology report of TUR-P samples indicated any form of malignancy, the patient was excluded from the study.
Ten days prior to surgery, patients stopped their current use of aspirin or Plavix (clopidogrel). The American Society of Anesthesiologists (ASA) classification was used to categorize the participants' health status before surgery. Prostate volume was measured by abdominal ultrasound with the formula V = a 9 b 9 c 9 p\6, where a is the transverse diameter, b is the anterior-posterior diameter, c is the longitudinal diameter, and p\6 is 0.52. The participants were randomized into two groups: treatment and placebo. This was carried out by our associate anesthesiologist during the preoperative visit by assigning random numbers from a random number table. The surgeon and patients were unaware of the grouping. As participants were told that the drug was in the form of a normal saline solution, there was no need for placebo preparation.
The treatment group received 2 g of fibrinogen concentrate (Haemocomplettan P; CSL Behring, Marburg, Germany) intravenously, diluted in 50 mL of water for injection, as instructed by the manufacturer, 15-30 min before the surgery by an anesthesiology technician who was not involved further in the study. The placebo group received the same volume of normal saline solution. All TUR-P surgeries were performed by a single surgeon under spinal anesthesia. The study was performed in accordance with the Declaration of Helsinki on good clinical practice. Our local medical ethics committee at the site approved the study protocol. The study protocol was also registered at the registry of clinical trials (IRCT201305097457N13) before recruitment was commenced. All participants signed an informed consent form before the screening procedure was begun.
Operation technique and measurements
All TUR-P surgeries were performed with a 26-Fr continuous irrigating resectoscope with room temperature irrigating fluid (distilled water). The irrigating fluid was collected and measured. Surgical blood loss was determined from the amount of hemoglobin in the irrigated fluid by use of the cyanomethemoglobin/colorimetric technique and spectrophotometer (Eppendorf, Hauppauge, NY, USA) device, with an accuracy of 0.001 g dL
À1
. To calculate the amount of blood loss during surgery, the estimated hemoglobin amount was then put into the following equation: preoperative hemoglobin (g dL À1 ) 9 blood loss (mL) = amount of irrigating fluid
. Operation time was defined as the time from the start of prostate resection until three-way urethral Foley catheter insertion. The resected tissue was weighed and sent for histologic evaluation. The serum hemoglobin level was checked 6 h and 24 h following surgery. The irrigating fluid (normal saline) from the recovery room and ward was also collected and measured. Postoperative blood loss was calculated with a previously described method.
As a confounding variable for the amount of bleeding, blood pressure was measured at both the start and completion of resection. After surgery, blood pressure was checked every 3 h by nursing staff, and the mean blood pressure was recorded as the ward blood pressure. Then, mean arterial pressure was also calculated. Checking of postoperative irrigation and blood pressure continued until 7 a.m. on the morning following surgery (the morning visit). If there were no complications, the participants were discharged on the second day following surgery, after removal of the urinary catheter. All participants were monitored for any adverse reactions to fibrinogen, including allergic reactions and thromboembolic episodes (myocardial infarction or pulmonary embolism), during the admission period and at a follow-up visit a week later.
Outcome measures
The primary endpoints were the effects of fibrinogen concentrate on the amount of bleeding during and after surgery. The secondary endpoints were the effects of fibrinogen concentrate on the amount of blood transfusion, the volume of irrigating fluid used, operation time, and safety.
Statistical analysis
Because, to our knowledge, this is the first study that has used fibrinogen concentrate in TUR-P patients, we based our calculations for sample size on the study of Karlsson et al. [13] during research design. We defined a as 95% before the study. The test was two-sided, and the number for each group was calculated with 82% statistical power. The actual number was 14 patients per group but, because of the possibility of patient loss, we chose 31 patients for fibrinogen treatment and 29 patients for the placebo group. The study groups' results were compared by use of Student's t-test, the Mann-Whitney U-test, the Pearson chisquare test, and Fisher's exact test. The correlation between the amount of bleeding and the resected tissue weight was determined with the Pearson correlation (bivariate analysis) test. Missing data for the patients who withdrew after treatment were imputed from the last observation performed. All statistical analyses were performed with SPSS version 22.0 (SPSS, Chicago, IL, USA). P-values of < 0.05 were considered to be statistically significant.
Results
A total of 60 participants (fibrinogen group, n = 31; and placebo group, n = 29) were eligible for analysis. The only difference between the two groups was in the mean plasma fibrinogen level, which was lower in the fibrinogen group: 259 mg dL À1 versus 282 mg dL À1 , P = 0.04 (difference 23 mg dL À1 ; 95% confidence interval [CI] 13-33) ( Table 1 ). The participants were also categorized on the basis of ASA score into five groups, which were statistically similar. During TUR-P surgery, no statistically significant difference was seen in the amount of bleeding between the two groups (521 mL versus 557 mL in the fibrinogen and placebo groups, respectively; difference 36 mL; 95% CI 24-48). Also, no differences were seen in other intraoperative parameters, such as resection time, resected tissue weight, and irrigating fluid volume. Postoperative variable analysis (blood loss, irrigating fluid volume used, and irrigation time) also did not reveal any differences. The hemoglobin level was statistically similar in both groups at 6 h (12.26 g dL À1 versus 12.16 g dL À1 for the fibrinogen and placebo groups, respectively; difference 0.1 g dL
À1
; 95% CI 0-0.9) and 24 h (11.60 g dL À1 versus
12.00 g dL À1 for the fibrinogen and placebo groups, respectively; difference 0.4 g dL À1 ; 95% CI 0-2) after surgery. The means of arterial blood pressure in both the fibrinogen group and the placebo group were similar at the start (122 mmHg versus 117 mmHg for the fibrinogen and placebo groups, respectively; difference 5 mmHg; 95% CI 0-10.5) and completion (124 mmHg versus 119 mmHg for the fibrinogen and placebo groups, respectively; difference 5 mmHg; 95% CI 0-10.5) of resection. The means of arterial pressure in the ward were also similar (113 mmHg versus 108 mmHg in the fibrinogen and placebo groups, respectively; difference 5 mmHg; 95% CI 0-10.5) ( Table 2) . A participant in the placebo group (3.4%) required an intervention for clot retention and secondary hemostasis, and another participant in the fibrinogen group (3.2%) required admission to the intensive care unit because of hypertension crisis following surgery. No significant morbidities caused by fibrinogen, including TUR-P syndrome or adverse outcomes, were observed in our study. In four participants in the fibrinogen group (12.9%), the amount of bleeding after surgery was so low that the spectrophotometer device could not read any hemoglobin level, and was set at zero. This also occurred in two participants (6.8%) in the placebo group (P = 0.7).
All participants were discharged on the second day following surgery, after removal of the urethral catheter. Postoperative blood transfusion was needed in one (3.2%) and five (17.2%) participants in the fibrinogen group and the placebo group, respectively (P = 0.2). A correlation was observed between the amount of intraoperative blood loss and resected prostate weight (r 2 = 0.341, P = 0.000). This correlation did not exist for postoperative bleeding (r 2 = 7.9 9 10
À4
, P = 0.83) (Figs 2  and 3) . None of our participants showed any sign of thromboembolism during admission and at the follow-up visit a week later.
Discussion
The main finding of this clinical trial was that preoperative administration of fibrinogen concentrate cannot reduce bleeding during and after TUR-P surgery. No complications because of its use were detected, and its safety was again demonstrated, which is consistent with the findings of previous studies [13, 14, 18] . Moreover, no increase in operation time or the amount of irrigating fluid required was observed. Therefore, it is likely that fibrinogen concentrate has no harmful effects during surgery. As mentioned previously, this is the first randomized clinical trial that has used fibrinogen concentrate in TUR-P surgery. There could be a number of reasons for our negative results. The most obvious one is that, despite serious bleeding during prostatectomy surgery, the bleeding is not high enough to cause dilutional coagulopathy. On the other hand, the bleeding during TUR-P surgery largely depends on the resected adenoma weight [2, 6, 7] . However, we did not consider any cut-off limit for the amount of resected adenoma. Our weight range was very wide (5-45 g). If we had recruited only participants with large resected adenomas, i.e. > 20 g, we might have obtained positive results.
Another important issue was the preoperative fibrinogen level in our groups, which was significantly lower in the treatment group. This is a major limitation that could have caused serious deviation in our study results, possibly because we compensated for their lower level by fibrinogen supplementation, and this might account for our non-significant results. Furthermore, as we wanted to determine the clinical effect of fibrinogen supplementation on reducing hemorrhage, the postoperative serum fibrinogen level was not measured, and this has created another limitation in our explanation of the results. Fibrinogen supplementation does not always increase the serum fibrinogen level. In this regard, Jeppsson et al. [20] found an even lower postoperative fibrinogen level in their treatment group. Also, 2 g of the concentrate might not be enough to increase the fibrinogen level. However, we cannot comment on this, because we did not have the postoperative serum fibrinogen levels.
The use of fibrinogen concentrate in urology is not new. In 2009, a randomized placebo-controlled clinical trial by Fenger-Eriksen et al. [14] showed that fibrinogen concentrate administration improved maximum clot firmness and reduced the transfusion of blood products in radical cystectomy patients whose lost blood was substituted by hydroxyethyl starch. Most studies on fibrinogen efficacy have been performed in situations where there is a high risk of severe bleeding, i.e. thoracic, cardiovascular and orthopedic surgery, and also in major trauma patients [11] [12] [13] [14] [15] [16] [17] [18] [19] . According to these studies, fibrinogen supplementation is effective, especially in an acquired hypofibrinogenemic state induced by massive bleeding.
In a randomized pilot study conducted in coronary artery bypass graft patients, Karlsson et al. [13] found that prophylactic fibrinogen concentrate reduced the amount of bleeding by 32% (P = 0.010). In another prospective double-blind clinical trial, Rahe-Meyer et al. [18] studied the effect of large doses of fibrinogen concentrate (median dose of 8 g) in patients undergoing elective thoracic or thoracoabdominal aortic replacement surgery involving cardiopulmonary bypass. They observed that their treatment group needed less allogeneic blood transfusion (P < 0.001). Similar reports exist in the field of orthopedic surgery research [17, 19] . In a comprehensive multicenter observational study on the use of fibrinogen concentrate in patients with massive hemorrhage [15] , Weiss et al. concluded that a positive correlation exists between postoperative plasma fibrinogen level and survival. They stated that a higher plasma fibrinogen level might be associated with a higher survival rate [15] .
No serious side effects were reported in any of these trials on the safety of using fibrinogen concentrate [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 25, 27, 28] . Furthermore, its clinical effectiveness and safety were compared with those of fresh frozen plasma in a systematic review by Kozek-Langenecker et al. [26] . They concluded that there is not enough evidence to support the clinical use of fresh frozen plasma, and that in some conditions it has a detrimental effect. However, there is much more consistent evidence in favor of fibrinogen concentrate over fresh frozen plasma in reducing blood loss and blood transfusion rate [26] .
Not all clinical trials on fibrinogen supplementation have resulted in positive outcomes. In a study on 249 participants by Wikkelso et al., fibrinogen supplementation was not effective in controlling postpartum hemorrhage [29] . Recently, the same group from Sweden who conducted the pilot study on the effectiveness of preoperative fibrinogen in coronary artery bypass surgery [13] published a randomized controlled study based on their gathered data [20] . This time, 48 participants were recruited (24 participants in each group); 2 g of fibrinogen concentrate was given before surgery to the treatment group, and the total blood loss during the first 12 h after surgery was measured. Median postoperative bleeding was not significantly different between the two groups (650 mL in the treatment group versus 730 mL in the placebo group, P = 0.29). Also, the proportion of transfused participants, the number of perioperative blood product transfusions and hemoglobin levels 24 h after surgery did not show any significant differences. The authors' explanation for these results was an incorrect hypothesis, in which they stated that fibrinogen supplementation reduces bleeding, plus an insufficient fibrinogen dose and a high cut-off preoperative fibrinogen level (< 3.8 g L À1 ).
In our study, we tried to exclude all of the known confounding factors for bleeding. Also, we tried to match our participants in all preoperative parameters, and our participant recruitment was unbiased. Some of our limitations were discussed above. The results showed a wide-ranging standard deviation in the amounts of intraoperative and postoperative bleeding (Table 2 ). This may indicate that another contributory variable is important in hemorrhage control that we might have missed. Furthermore, our limited participant numbers prevent us from generalizing the results. Nevertheless, we believe that, despite non-significant results, a 36-mL (6.5%) difference in intraoperative bleeding and a 50-mL (4.7%) decrease in postoperative bleeding (Table 2) are worth noting, and should be further investigated in a well-designed clinical trial with more participants. Further analysis of the amounts of total blood loss in both groups (812 mL in the fibrinogen group, and 898 mL in the placebo group) also did not show any significant difference (P = 0.6).
This is a new topic in urology surgery and, because the use of TUR-P is extensive, and because its effect in decreasing patient morbidity is undeniable, it is likely to be widely accepted by urologists. Looking at treatment costs, each vial of Haemocomplettan P costs approximately 400 US$ (costing 10 US$ for a patient with Iran's health insurance coverage). This is far less than the costs of admission and blood products, so, considering its benefits, it is cost-efficient.
Conclusions
Fibrinogen concentrate could not significantly decrease bleeding during and after TUR-P surgery. However, our study showed that it can be prescribed with no significant adverse effects. Further larger multicenter studies are required to learn more. 
